PROTAC及其在肿瘤治疗方面的应用

肿瘤的发生与肿瘤特异癌蛋白的表达密切相关,调控这些蛋白质的降解已成为肿瘤治疗的一种新方法。泛素介导的蛋白质降解通路控制着真核细胞内绝大多数蛋白质的选择性降解。近年来,一种人工合成的蛋白靶向降解嵌合分子(proteolysis targeting chimeric molecule,PROTAC),能通过利用细胞固有的泛素-蛋白酶体系统调控靶向蛋白质降解。本文总结了PROTAC的相关研究进展,虽然对PROTAC技术的研究还有很多尚待解决的问题,但其作为肿瘤治疗的新手段具有很大的潜力。     

蛋白降解靶向嵌合体临床前及临床研究进展

蛋白降解靶向嵌合体(proteolysis targeting chimera,PROTAC)是一种可以同时结合E3连接酶和靶蛋白的异双功能小分子,能够借助泛素-蛋白酶体系统特异性降解靶蛋白。目前PROTAC药物大多处于临床试验阶段,配体主要为非共价化合物,具有克服耐药性、降解“不可用药”靶蛋白的优势,但非共价配体会使PROTAC产生钩效应(hook effect),影响药效发挥。而共价配体凭借自身优势,可以避免该现象的发生,对于PROTAC的发展具有极大的帮助。本文总结了临床前及临床研究阶段,PROTAC分子在核内蛋白、跨膜蛋白和胞浆蛋白3种蛋白靶点中的应用,并以此为基础进行了讨论与展望,以期为今后PROTAC的发展提供一定的研究思路和参考。     

泛素蛋白酶体途径及其对植物生长发育的调控

泛素蛋白酶体途径主要由泛素活化酶、泛素结合酶、泛素蛋白连接酶和26S蛋白酶体组成。泛素活化酶首先激活泛素分子, 然后把泛素转移到泛素结合酶上。泛素结合酶结合泛素蛋白连接酶并把泛素转移到底物蛋白上使底物泛素化, 或把泛素转移到泛素蛋白连接酶再使底物泛素化。泛素化的蛋白通常通过26S蛋白酶体进行降解。初步的研究结果表明, 植物生长发育的很多方面受泛素蛋白酶体介导的蛋白降解途径的调控。     

泛素蛋白酶体途径及其对植物生长发育的调控

泛素蛋白酶体途径主要由泛素活化酶、泛素结合酶、泛素蛋白连接酶和26S蛋白酶体组成。泛素活化酶首先激活泛素分子,然后把泛素转移到泛素结合酶上。泛素结合酶结合泛素蛋白连接酶并把泛素转移到底物蛋白上使底物泛素化,或把泛素转移到泛素蛋白连接酶再使底物泛素化。泛素化的蛋白通常通过26S蛋白酶体进行降解。初步的研究结果表明,植物生长发育的很多方面受泛素蛋白酶体介导的蛋白降解途径的调控。     

去泛素化酶与肿瘤

泛素化修饰（ubiquitination modification）广泛存在于真核生物,通过26S蛋白酶体降解途径或信号传递等,改变蛋白质稳定性、定位和活性等功能,参与细胞的周期、转录、炎症、肿瘤和免疫等各项功能,是一类复杂的动态调控系统。泛素化调节是一个可逆过程,被泛素连接酶（ubiquitin ligase,E3）和去泛素化酶（deubiquitylase,DUB）拮抗调控。去泛素化酶可介导底物蛋白质去泛素化,调节蛋白质功能,参与细胞各项生命活动。去泛素化酶的蛋白质丰度、定位和催化活性等受到严格调控。在肿瘤的发生发展过程中,有许多与肿瘤相关的重要抑癌或者促癌蛋白质被去泛素化酶调控,而且去泛素化酶的表达异常、突变等都会影响细胞的DNA损伤修复、凋亡、自噬、分子信号通路和染色质重塑等,从而调控肿瘤细胞的生长侵袭和转移等过程。因此,去泛素化酶系统是参与肿瘤调控的重要蛋白质,也是肿瘤的重要药物靶标,已有多个小分子抑制剂用于抗肿瘤治疗的研发。本文主要总结介绍了泛素分子、泛素链特异性和去泛素化酶系统在肿瘤中的调节机制,为临床药物靶点的设计以及诊断指标等提供依据。     

蛋白质组学在去泛素化酶研究中的应用

泛素-蛋白酶体系统是细胞内蛋白质特异性降解的主要途径,参与并调控细胞周期、免疫应答、信号传递和DNA修复等真核生物体内几乎所有的生命活动。去泛素酶的存在使泛素化修饰成为可逆过程,保证了泛素系统及其相关生理过程的动态平衡,其表达紊乱也是诱发多种疾病的主要原因。对去泛素化酶进行系统、全面的研究是理解其作用机制并将其作为治疗药物靶点的前提。蛋白质组学技术的快速发展为系统深入研究去泛素化酶提供了条件,特别是在去泛素化酶的相互作用网络和底物特异性研究等方面发挥了独特的作用。因此,文中结合课题组研究工作,对去泛素化酶的分类及功能进行介绍并总结了蛋白质组学在去泛素化酶研究中的应用进展。     

Saposin C下调LNCaP细胞雄激素受体的多泛素化降解（英）

本研究旨在证实鞘脂活化蛋白C(saposin C)对雄激素受体（AR）多泛素化降解的影响及其机制. 通过将真核表达载体saposin C转染LNCaP细胞,发现saposin C上调AR的蛋白水平和转录激活活性. 进一步将野生型和突变型泛素质粒Ubwt和UbK48R分别与saposin C 共转染LNCaP细胞发现,saposin C能够促进AR蛋白的单泛素化形式的稳定性,抑制AR的多泛素化修饰及其在蛋白酶体中的降解. 其分子机制是saposin C、Ub和AR三者形成复合体,抑制了AR的进一步多泛素化过程. 同时还发现,在这一机制中,细胞内低浓度的雄激素（0.1 nmol/L）与saposin C具有协同作用.     

泛素信号途径、自噬受体与细胞选择性自噬

蛋白质泛素化是真核生物细胞内蛋白质合成后最重要和最普遍的修饰方式之一。发生在蛋白质底物上的泛素化,由于其泛素化方式及形成泛素链的连接形式的多样性,又统称为泛素信号途径。研究表明,泛素信号途径对蛋白质的调节作用分为降解相关和非相关的两种。细胞内蛋白质的降解主要通过泛素-蛋白酶体或溶酶体-自噬途径来完成。一般认为,通过泛素-蛋白酶体降解的蛋白质具有很强的选择性,而通过溶酶体-自噬途径降解的蛋白质一般选择性较差。然而,近年来,细胞自噬受体如p62等的发现则表明细胞自噬同样具有很强的选择性,这一类由细胞自噬受体介导的细胞自噬被称为细胞选择性自噬(Selective autophagy)。蛋白质泛素化及降解调控几乎所有类型的细胞活动;与之对应的是,蛋白质泛素化及降解异常与包括肿瘤在内的多种人类疾病的发生发展密切相关。本文综述了泛素信号途径调控蛋白质通过蛋白酶体或自噬途径降解的基本过程和部分最新进展,并结合本实验室的研究成果介绍泛素化修饰细胞自噬受体调控细胞选择性自噬的新机制。     

泛素化和磷酸化协同作用调控蛋白质降解

在真核细胞中,泛素化和磷酸化是2种常见的蛋白质修饰方式。泛素在蛋白酶体降解途径中发挥重要的靶向作用,细胞外信号严格调控着目的蛋白的泛素化。在很多情况下,这种调控依赖于蛋白质的磷酸化。由磷酸化影响的调控步骤可能与E3泛素连接酶对底物的识别有关,也可能与实际的交联反应有关。这种调控是通过对底物或E3连接酶本身的磷酸化实现的。     

去泛素化酶在肾细胞癌中的作用

肾细胞癌（renal cell carcinoma,RCC）是成人肾脏的原发性恶性肿瘤。泛素-蛋白酶体系统（ubiquitin-proteasome system,UPS）对控制蛋白质水平和调节生理病理过程至关重要。去泛素化酶（deubiquitinases,DUBs）是UPS的关键成分,特别是从靶蛋白中去除泛素链,通过严格调节正常生理学中泛素化和去泛素化之间的平衡,对蛋白质稳态和质量控制显示出至关重要的作用。越来越多的研究表明,功能异常的DUBs与RCC的进展和转移有关。根据底物的不同,一些DUB可能会抑制RCC,而另一些则促进。本文综述了RCC相关DUB的最新研究进展,描述了其分类、功能作用,总结了DUB在RCC中的作用和作用机制,并讨论了靶向DUBs用于癌症治疗。     

靶向蛋白质降解技术研究进展

靶向蛋白质降解技术可有效克服DNA敲除、RNA干扰等传统药物靶点确认及干扰策略的局限性。近年来,一系列新型靶向蛋白质降解技术不断涌现,在药物研发领域展现出极好的应用前景。本文综述了靶向蛋白质降解技术的最新研究进展,重点介绍各种技术的作用机制、应用情况、技术优势及目前存在问题,以期为药物靶点确认及新药开发提供有力理论及技术支持。     

Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation

The proteome contains hundreds of proteins that in theory could be excellent therapeutic targets for the treatment of human diseases. However, many of these proteins are from functional classes that have never been validated as viable candidates for the development of small molecule inhibitors. Thus, to exploit fully the potential of the Human Genome Project to advance human medicine, there is a need to develop generic methods of inhibiting protein activity that do not rely on the target protein's function. We previously demonstrated that a normally stable protein, methionine aminopeptidase-2 or MetAP-2, could be artificially targeted to an Skp1-Cullin-F-box (SCF) ubiquitin ligase complex for ubiquitination and degradation through a chimeric bridging molecule or Protac (proteolysis targeting chimeric molecule). This Protac consisted of an SCF(beta-TRCP)-binding phosphopeptide derived from IkappaBalpha linked to ovalicin, which covalently binds MetAP-2. In this study, we employed this approach to target two different proteins, the estrogen (ER) and androgen (AR) receptors, which have been implicated in the progression of breast and prostate cancer, respectively. We show here that an estradiol-based Protac can enforce the ubiquitination and degradation of the alpha isoform of ER in vitro, and a dihydroxytestosterone-based Protac introduced into cells promotes the rapid disappearance of AR in a proteasome-dependent manner. Future improvements to this technology may yield a general approach to treat a number of human diseases, including cancer.     

Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation

In eukaryotes, endoplasmic reticulum-associated degradation (ERAD) functions in cellular quality control and regulation of normal ER-resident proteins. ERAD proceeds by the ubiquitin-proteasome pathway, in which the covalent attachment of ubiquitin to proteins targets them for proteasomal degradation. Ubiquitin-protein ligases (E3s) play a crucial role in this process by recognizing target proteins and initiating their ubiquitination. Here we show that Hrd1p, which is identical to Der3p, is an E3 for ERAD. Hrd1p is required for the degradation and ubiquitination of several ERAD substrates and physically associates with relevant ubiquitin-conjugating enzymes (E2s). A soluble Hrd1 fusion protein shows E3 activity in vitro - catalysing the ubiquitination of itself and test proteins. In this capacity, Hrd1p has an apparent preference for misfolded proteins. We also show that Hrd1p functions as an E3 in vivo, using only Ubc7p or Ubc1p to specifically program the ubiquitination of ERAD substrates.     

Targeting protein quality control pathways in breast cancer

The efficient production, folding, and secretion of proteins is critical for cancer cell survival. However, cancer cells thrive under stress conditions that damage proteins, so many cancer cells overexpress molecular chaperones that facilitate protein folding and target misfolded proteins for degradation via the ubiquitin-proteasome or autophagy pathway. Stress response pathway induction is also important for cancer cell survival. Indeed, validated targets for anti-cancer treatments include molecular chaperones, components of the unfolded protein response, the ubiquitin-proteasome system, and autophagy. We will focus on links between breast cancer and these processes, as well as the development of drug resistance, relapse, and treatment.     

蛋白质SUMO化和泛素化修饰的关系

泛素化和SUMO化是蛋白质翻译后修饰的重要方式,广泛参与调节蛋白质功能和细胞生命活动各个环节。多聚泛素化降解蛋白质,而SUMO化主要调节蛋白质的相互作用和定位等。在不同情况下,SUMO化和泛素化既可协同调节蛋白质功能,也可相互拮抗。最近研究发现,某些底物的SUMO化能够激活体内一类新发现的SUMO依赖的泛素连接酶,启动泛素-蛋白酶体途径降解底物,导致蛋白质SUMO化和汔素化的关系进一步精细化和复杂化。     

Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases

Although radiotherapy represents one of the most effective treatment modalities for patients with cancer, inherent and/or acquired resistance of cancer cells to radiotherapy is often an impediment to effective treatment. Diverse strategies have been developed to improve the efficacy of radiotherapy. The ubiquitin-proteasome system (UPS) operates in numerous vital biologic processes by controlling the protein turnover in cells. Ubiquitination is central to the UPS pathway, and it relies on the E3 ubiquitin ligases to catalyze the covalent attachment of ubiquitin to its protein substrates. Cullin-based RING ligases (CRLs) are the largest family of E3 ligases that are responsible for the ubiquitination and destruction of numerous cancer-relevant proteins. Its deregulation has been linked to many human cancers, making it an attractive target for therapeutic intervention. This review discusses how targeting the ubiquitin-proteasome system, particularly CRLs, is an exciting new strategy for radiosensitization in cancer and, specifically, focuses on MLN4924, a recently discovered small-molecule inhibitor of the NEDD8-activating enzyme, which is being characterized as a novel radiosensitizing agent against cancer cells by inactivating CRL E3 ubiquitin ligases.     

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules and allow selective protein degradation by addressing the natural ubiquitin proteasome system. As this new strategy of chemically induced protein degradation can serve as a biological tool and provides new possibilities for drug discovery, it has been applied to a variety of targets including (nuclear) receptors, kinases, and epigenetic proteins. A lot of PROTACs have already been designed in the field of epigenetics, and their synthesis and characterization highly contributed to structural optimization and improved mechanistic understanding of these molecules. In this review, we will discuss and summarize recent advances in PROTAC discovery with focus on epigenetic targets.